236 related articles for article (PubMed ID: 31526463)
21. Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V
Metzenmacher M; Goetz M; Herold T; Stuschke M; Aigner C; Darwiche K; Eberhardt WE; Schuler M; Wiesweg M
Clin Lung Cancer; 2021 Sep; 22(5):e668-e672. PubMed ID: 33551244
[No Abstract] [Full Text] [Related]
22. [Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer].
Deng L; Yang Y; Huang J
Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):73-80. PubMed ID: 38296628
[TBL] [Abstract][Full Text] [Related]
23. BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.
Leonetti A; Facchinetti F; Rossi G; Minari R; Conti A; Friboulet L; Tiseo M; Planchard D
Cancer Treat Rev; 2018 May; 66():82-94. PubMed ID: 29729495
[TBL] [Abstract][Full Text] [Related]
24. A BRAF new world.
Frisone D; Friedlaender A; Malapelle U; Banna G; Addeo A
Crit Rev Oncol Hematol; 2020 Aug; 152():103008. PubMed ID: 32485528
[TBL] [Abstract][Full Text] [Related]
25. BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
Caparica R; de Castro G; Gil-Bazo I; Caglevic C; Calogero R; Giallombardo M; Santos ES; Raez LE; Rolfo C
Crit Rev Oncol Hematol; 2016 May; 101():32-9. PubMed ID: 26960735
[TBL] [Abstract][Full Text] [Related]
26. Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions.
Riudavets M; Cascetta P; Planchard D
Lung Cancer; 2022 Jul; 169():102-114. PubMed ID: 35696864
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer
with Rare Mutation].
Li T; Li J
Zhongguo Fei Ai Za Zhi; 2021 Jan; 24(1):19-24. PubMed ID: 33478186
[TBL] [Abstract][Full Text] [Related]
28. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
29. Dabrafenib Active in Rare NSCLC Subtype.
Cancer Discov; 2016 Jul; 6(7):OF4. PubMed ID: 27207893
[TBL] [Abstract][Full Text] [Related]
30. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.
Myall NJ; Neal JW; Cho-Phan CD; Zhou LY; Stehr H; Zhou L; Diehn M; Wakelee HA
Clin Lung Cancer; 2016 Mar; 17(2):e17-21. PubMed ID: 26776917
[No Abstract] [Full Text] [Related]
32. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H
Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339
[TBL] [Abstract][Full Text] [Related]
33. Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer.
Mezquita L; Oulhen M; Aberlenc A; Deloger M; Aldea M; Honore A; Lecluse Y; Howarth K; Friboulet L; Besse B; Planchard D; Farace F
Br J Cancer; 2024 Mar; 130(4):682-693. PubMed ID: 38177660
[TBL] [Abstract][Full Text] [Related]
34. [Mutation of the BRAF genes in non-small cell lung cancer].
Huang Z; Wu Y
Zhongguo Fei Ai Za Zhi; 2012 Mar; 15(3):183-6. PubMed ID: 22429583
[TBL] [Abstract][Full Text] [Related]
35. Successful re-challenge of dabrafenib-trametinib combination therapy in advanced
Xue Y; Ren Y; Yan B; Li Z; Huang C
Ann Transl Med; 2022 Sep; 10(18):1029. PubMed ID: 36267742
[TBL] [Abstract][Full Text] [Related]
36. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
Sen B; Peng S; Tang X; Erickson HS; Galindo H; Mazumdar T; Stewart DJ; Wistuba I; Johnson FM
Sci Transl Med; 2012 May; 4(136):136ra70. PubMed ID: 22649091
[TBL] [Abstract][Full Text] [Related]
37. Patients with non-small-cell lung cancer harbouring a
Auliac JB; Bayle S; Vergnenegre A; Le Caer H; Falchero L; Gervais R; Doubre H; Vinas F; Marin B; Chouaid C
Curr Oncol; 2018 Oct; 25(5):e398-e402. PubMed ID: 30464690
[TBL] [Abstract][Full Text] [Related]
38. [Expert consensus on the diagnosis and treatment in advanced non-small cell lung cancer with BRAF mutation in China].
Lung Cancer Professional Committee of Chinese Anti-Cancer Association
Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):279-290. PubMed ID: 37078209
[TBL] [Abstract][Full Text] [Related]
39. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Gautschi O; Milia J; Cabarrou B; Bluthgen MV; Besse B; Smit EF; Wolf J; Peters S; Früh M; Koeberle D; Oulkhouir Y; Schuler M; Curioni-Fontecedro A; Huret B; Kerjouan M; Michels S; Pall G; Rothschild S; Schmid-Bindert G; Scheffler M; Veillon R; Wannesson L; Diebold J; Zalcman G; Filleron T; Mazières J
J Thorac Oncol; 2015 Oct; 10(10):1451-7. PubMed ID: 26200454
[TBL] [Abstract][Full Text] [Related]
40. BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
Dudnik E; Peled N; Nechushtan H; Wollner M; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadari N; Urban D; Mishaeli M; Zer A; Allen AM; Rabinovich NM; Rotem O; Kuznetsov T; Shochat T; Roisman LC; Bar J;
J Thorac Oncol; 2018 Aug; 13(8):1128-1137. PubMed ID: 29723688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
